HOME >> MEDICINE >> NEWS
Asthmatx completes enrollment in pivotal study of bronchial thermoplasty

San Francisco, CA, May 21, 2007 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.

Leading asthma and bronchoscopy experts are participating in this international, multicenter AIR2 Trial to establish the safety and efficacy of the Alair System. Nearly 300 patients were enrolled in the study during the last 18 months at over 30 world-renowned medical centers including 15 US research hospitals. The AIR2 Trial is the fourth clinical study of the Alair Bronchial Thermoplasty System. To date, over 700 bronchoscopic procedures have been performed on asthma patients.

"We are very pleased to be a participant in this very important AIR2 Trial, the success of which will result in an important advancement in the treatment of severe asthma," states Mario Castro, MD, Associate Professor at the Washington University School of Medicine and Asthma Center, and a Principal Investigator in the AIR2 Trial. "As the lead enrolling center in the United States, we have experienced significant patient interest in bronchial thermoplasty, which we hope may become a new option for patients with difficult-to-treat asthma."

Final results of the first randomized and controlled clinical study of bronchial thermoplasty, the Asthma Intervention Research (AIR) Trial, were also reported today at the annual scientific assembly of the American Thoracic Society (ATS) by Gerard Cox, MB, Professor of Medicine, McMaster University, Canada, and principal investigato
'"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
21-May-2007


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Approval to start US BTT pivotal trial
6. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
7. New data show CAS in clinical practice has comparable MAE rate with pivotal sapphire trial
8. Now is a pivotal point in history to abolish state execution
9. Orqis Medical receives unconditional FDA approval for pivotal trial of percutaneous CHF therapy
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. Penn study finds pro-death proteins required to regulate healthy immune function

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security ... kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 26, 2017 , ... ... of optimize lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry ... , This webinar will discuss freeze drying techniques, as well as new accessories and ...
(Date:7/26/2017)... Maryland (PRWEB) , ... July ... ... Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation ... These concurrent events offer comprehensive solutions to process validation lifecycle challenges faced ...
(Date:7/26/2017)... ... 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is excited to announce the 106 college athletes with type 1 diabetes who ... 2005, the Team Type 1 Foundation has bestowed a total of 271 college scholarships ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
Breaking Medicine Technology:
Cached News: